motixafortide

REMS

Mobilizes hematopoietic stem cells to peripheral blood for collection and use in autologous transplantation in patients with multiple myeloma (in combination with filgrastim).

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity;
Leukemia;
OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Rep: Women of reproductive potential;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypertension

Derm: erythema, flushing, pruritus, rash, urticaria

F and E: hypokalemia

GI: nausea

Hemat: leukocytosis, tumor cell mobilization

Local: injection site reactions

MS: back pain

Neuro: paresthesia, dizziness, tremor

Misc: chills, fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions ⬆ ⬇

Drug-drug:

None reported.

Availability ⬆ ⬇

Lyophilized powder for injection: 62 mg/vial

Route/Dosage ⬆ ⬇

SC (Adults ): Following pretreatment with filgrastim for 4 days: 1.25 mg/kg (using actual body weight) once daily given 10–14 hr prior to the initiation of the first apheresis. A second dose of 1.25 mg/kg (using actual body weight) can be administered 10–14 hr before a third apheresis, if needed.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Inhibits the CXCR-4 chemokine receptor, which decreases adherence of stem cells to bone marrow, freeing them up to mobilize to peripheral blood.

Therapeutic effects:

Mobilization of stem cells to peripheral blood allowing collection.

Classifications ⬆ ⬇

Therapeutic Classification: none assigned

Pharmacologic Classification: hematopoietic stem cell mobilizers

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed following SUBQ administration.

Distribution: Largely confined to extravascular fluid space.

Protein Binding: >99%.

Metabolism/Excretion: Undergoes catabolism into small peptides and individual amino acids. Primarily excreted in the urine.

Half-Life: 2 hr.

Time/Action Profile ⬆ ⬇

(mobilization of stem cells)

ROUTE	ONSET	PEAK	DURATION
SUBQ	unknown	16 hr	unknown

*With filgrastim pretreatment.

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of medication to patient. Advise patient to read Patient Information before starting therapy.
Advise patient to notify health care professional immediately if injection site reaction, fever, chills, nausea, flushing, rash, dizziness, or difficulty breathing occur.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking other medications.
Rep: May cause fetal harm. Advise women of reproductive potential to use effective contraception during therapy with motixafortide and for 8 days after the final dose. Advise patients not to breastfeed during therapy and for 8 days after final dose.

section name header

Indications ⬇